Geode Capital Management LLC Decreases Stock Holdings in Entrada Therapeutics, Inc. (NASDAQ:TRDA)

Geode Capital Management LLC lowered its position in Entrada Therapeutics, Inc. (NASDAQ:TRDA) by 0.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 573,891 shares of the company’s stock after selling 2,560 shares during the period. Geode Capital Management LLC owned approximately 1.53% of Entrada Therapeutics worth $9,925,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Vanguard Group Inc. grew its holdings in Entrada Therapeutics by 19.7% in the fourth quarter. Vanguard Group Inc. now owns 1,464,237 shares of the company’s stock worth $25,317,000 after purchasing an additional 241,052 shares during the last quarter. State Street Corp increased its position in Entrada Therapeutics by 5.5% during the 3rd quarter. State Street Corp now owns 469,601 shares of the company’s stock valued at $7,504,000 after buying an additional 24,385 shares in the last quarter. Arrowstreet Capital Limited Partnership raised its stake in Entrada Therapeutics by 123.2% in the fourth quarter. Arrowstreet Capital Limited Partnership now owns 222,520 shares of the company’s stock valued at $3,847,000 after buying an additional 122,823 shares during the last quarter. Charles Schwab Investment Management Inc. boosted its holdings in Entrada Therapeutics by 6.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 197,127 shares of the company’s stock worth $3,408,000 after acquiring an additional 11,143 shares in the last quarter. Finally, American Century Companies Inc. grew its stake in shares of Entrada Therapeutics by 17.7% during the fourth quarter. American Century Companies Inc. now owns 59,710 shares of the company’s stock worth $1,032,000 after acquiring an additional 8,985 shares during the last quarter. Institutional investors own 86.39% of the company’s stock.

Wall Street Analysts Forecast Growth

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $20.00 price objective on shares of Entrada Therapeutics in a research report on Monday, March 31st.

Entrada Therapeutics Stock Performance

Shares of TRDA opened at $8.71 on Wednesday. The stock has a 50-day moving average of $10.12 and a two-hundred day moving average of $14.47. The stock has a market cap of $327.45 million, a P/E ratio of 5.48 and a beta of 0.04. Entrada Therapeutics, Inc. has a one year low of $7.10 and a one year high of $21.79.

Entrada Therapeutics (NASDAQ:TRDA) last released its quarterly earnings data on Thursday, February 27th. The company reported $0.03 earnings per share for the quarter, topping analysts’ consensus estimates of ($0.66) by $0.69. The firm had revenue of $12.25 million for the quarter, compared to analyst estimates of $11.95 million. Entrada Therapeutics had a net margin of 25.53% and a return on equity of 16.11%. Analysts predict that Entrada Therapeutics, Inc. will post 1.12 EPS for the current fiscal year.

About Entrada Therapeutics

Entrada Therapeutics, Inc, a clinical-stage biotechnology company, develops endosomal escape vehicle (EEV) therapeutics for the treatment of multiple neuromuscular diseases. Its EEV platform develops a portfolio of oligonucleotide, antibody, and enzyme-based programs. Its therapeutic candidates, which include ENTR-601-44, which is in Phase I clinical trial for the treatment of Duchenne muscular dystrophy; and ENTR-701, which is in Phase 1/2 clinical trial for the treatment of myotonic dystrophy type 1.